Teriparatide Efficacy in the Treatment of Severe Hypocalcemia After Kidney Transplantation in Parathyroidectomized Patients: A Series of Five Case Reports
Authors:
- Estela L. NogueiraENEstela L. Nogueira
- Ana C. CostaACAna C. Costa
- Alice SantanaASAlice Santana
- José O. GuerraJGJosé O. Guerra
- Sónia SilvaSSSónia Silva
- Clara Mil-HomensCMClara Mil-Homens
- António G. CostaACAntónio G. Costa
- 15 August 2011
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 92 (3) , 316-320
Abstract
Teriparatide is a recombinant human parathormone (PTH 1-34) currently approved for the treatment of osteoporosis with high risk of fracture. In this study, we analyze the efficacy and safety profile of teriparatide therapy in severe and prolonged hypocalcemia after kidney transplantation in patients previously submitted to parathyroidectomy. The authors report results from a series of five hemodialyzed patients (mean age: 50±15 years; three female) previously submitted to parathyroidectomy to control secondary hyperparathyroidism. All patients had developed severe refractory hypocalcemia (calcium minimum levels: 5±1.4 mg/dL) early after kidney transplantation. The effect of teriparatide in calcemia and phosphatemia levels was analyzed, and variations in calcium and vitamin D analog requirements were analyzed. Secondary effects and serum creatinine changes were also ascertained. Teriparatide therapy was initiated 32±14 days after the development of hypocalcemia. As a result, calcemia levels increased (median±standard deviation [SD]: 6.7±0.8 vs. 8.5±0.8 mg/dL, P=0.024) allowing suspension of intravenous calcium in two patients and reduction of calcitriol doses (mean±SD: 1.1±0.38 vs. 0.55±0.27 μg/day, P=0.004). In addition, phosphatemia levels (median±SD: 5.1±1.5 vs. 3.9±0.5 mg/dL, P=0.09) and calcium carbonate requirements (mean±SD: 13.8±9.4 vs. 7.2 ±3.7 g/day, P=0.9) exhibited declining trends. No secondary effects were observed and creatinemia remained stable. Our data strongly suggest that refractory hypocalcemia after kidney transplantation in patients with low PTH levels can be successfully treated with teriparatide. PTH analog therapy leads to faster normalization of calcemia, permits earlier suspension of intravenous calcium supplementation, and reduces calcitriol requirements.Keywords
This publication has 18 references indexed in Scilit:
- Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1–34): A Pilot StudyKidney and Blood Pressure Research, 2010
- Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTHHemodialysis International, 2009
- Calcium Metabolism in the Early Posttransplantation PeriodClinical Journal of the American Society of Nephrology, 2009
- Sporadic Hypoparathyroidism Treated with Teriparatide: A Case Report and Literature ReviewExperimental and Clinical Endocrinology & Diabetes, 2007
- Effect of Parathyroid Hormone Administration in a Patient with Severe Hypoparathyroidism Caused by Gain-of-function Mutation of Calcium-sensing ReceptorEndocrine Journal, 2006
- Teriparatide (Biosynthetic Human Parathyroid Hormone 1–34): A New Paradigm in the Treatment of OsteoporosisBasic & Clinical Pharmacology & Toxicology, 2004
- Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1–34)VersusCalcitriol and CalciumThe Journal of Clinical Endocrinology & Metabolism, 2003
- Parathyroidectomy: Whom and when?Kidney International, 2003
- A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1-34 in Treatment of HypoparathyroidismThe Journal of Clinical Endocrinology & Metabolism, 1998
- Hungry bone syndrome: Clinical and biochemical predictors of its occurrence after parathyroid surgeryThe American Journal of Medicine, 1988